2015
DOI: 10.5694/mja15.01015
|View full text |Cite
|
Sign up to set email alerts
|

Successful treatment of ACE inhibitor‐induced angioedema with icatibant, a bradykinin B2 receptor antagonist

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 10 publications
(17 reference statements)
0
5
0
Order By: Relevance
“…Intubation and tracheotomy were avoided in several cases following icatibant administration. 35,[40][41][42]46,48 Icatibant was not successful in one case; however, the reason for lack of benefit in this case is unknown. 38 Two case series comparing icatibant-treated patients with those previously treated with standard therapies found statistically significant improvements in time to complete symptom resolution.…”
Section: Discussionmentioning
confidence: 94%
See 3 more Smart Citations
“…Intubation and tracheotomy were avoided in several cases following icatibant administration. 35,[40][41][42]46,48 Icatibant was not successful in one case; however, the reason for lack of benefit in this case is unknown. 38 Two case series comparing icatibant-treated patients with those previously treated with standard therapies found statistically significant improvements in time to complete symptom resolution.…”
Section: Discussionmentioning
confidence: 94%
“…8,9,15,35,43 Several case reports and case series illustrate the efficacy of icatibant in the management of these events. 34-45 In the majority of these patients, icatibant was used as a second- or third-line therapy with successful symptom resolution ranging from 10 to 30 minutes or 4 to 10 hours. Intubation and tracheotomy were avoided in several cases following icatibant administration.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Initial PubMed search identified eleven case reports that described the use of icatibant as a treatment for ACE-inhibitor induced angioedema of the head and neck, with mixed results among cases. [3][4][5][6][7][8][9][10][11][12][13] Three of the results from the literature search included clinical trials, which offered more robust study designs and results than the aforementioned case reports. Baş et al first reported in 2015 that icatibant does offer potential benefits when used as a treatment for ACE-inhibitor induced angioedema of the head and neck.…”
Section: Related Literaturementioning
confidence: 99%